The anti-tumor immune response involves a series of complex steps mediated by various immune cells and signaling molecules.

The American Cancer Society reports that five-year cancer survival in the US has reached a historic high of 70% for the first ...

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities. Tevogen Bio plans to ...

Ipsen has gambled up to $610 million on a new class of bispecific T-cell engagers. The biobuck bet has landed the French drugmaker exclusive global rights to a preclinical Biomunex Pharmaceuticals ...

Cytotoxic T cells are star players in the adaptive immune system, enforcing protection against invading viruses or cancer cells. However, evidence has been mounting that the cells may also deal a ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...

As the trained killers of the immune system, cytotoxic T cells silently save our lives every day—vanquishing viruses before they can run amok, and putting nascent cancer cells out of business before ...

A study published in Nature Communications examined the use of calcium carbonate nanoparticles (CNPs) to improve the activation and function of cytotoxic T lymphocytes (CTLs) in cancer immunotherapy.